Navigation Links
Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer
Date:12/14/2007

CARLSBAD, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that its Board of Directors has promoted B. Lynne Parshall, J.D. to Chief Operating Officer, effective immediately. Ms. Parshall retains her position as Chief Financial Officer, and is a Director of the Company.

"This promotion is well-deserved, and appropriately reflects the scope of Lynne's responsibilities at Isis," commented Stanley Crooke, M.D., Ph.D., Isis' President and CEO. "Lynne has been an integral part of Isis' management team for many years, and has been performing COO functions now for quite some time. This promotion recognizes her outstanding contributions and the nature of her current role with the Company."

Ms. Parshall joined Isis in November 1991, and she has served as Director since 2000, Executive Vice President since 1995, Chief Financial Officer since 1994 and Secretary since 1991. Ms. Parshall is currently responsible for overseeing the operations of finance, legal, patents, manufacturing and business development and is also very involved in the Company's corporate communications activities. Previously, Ms. Parshall was a Partner with the firm of Cooley Godward LLP, now Cooley Godward Kronish LLP, where she represented several health care companies in a general practice specializing in corporate partnering and other technology-based transactions. Ms. Parshall received her J.D. at Stanford Law School, Stanford, California and her B.A. from Harvard University, Cambridge, Massachusetts. Ms. Parshall is on the board of CardioDynamics International Corporation and is a Trustee of The Bishop School in La Jolla. Ms. Parshall is also a member of the Licensing Executives Society and a member of the American, California, and San Diego bar associations.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis Pharmaceuticals and the Company's business. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward- looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended September 30, 2007, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 18, 2017 , ... ... . The move comes after the company changed focus to making analytical tools ... brand and our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert ...
(Date:4/19/2017)... ... April 19, 2017 , ... WHO: Peggy Lillis ... through education and advocacy. Founded in 2010 in memory of a single-parent mom ... foundation has become the most-consulted source for patient-focused information on C. diff infections ...
(Date:4/19/2017)... April 19, 2017  As a Bronze ... Heroin Summit ,  Proove® Biosciences, Inc. announces ... environmental, and lifestyle factors to accurately predict prescription ... of Southern California (USC), the Interventional Pain Institute ... publish results showing that Proove Opioid Risk® accurately ...
(Date:4/19/2017)... April 19, 2017   Thermo Fisher Scientific ... multi-center Procalcitonin MOnitoring SEpsis (MOSES) Study have been ... Critical Care Medicine . Researchers from the ... Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring ... B·R·A·H·M·S PCT (procalcitonin) assay to assess risk for ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has ... World Lung Imaging Workshop at the University of Pennsylvania. ... invited to deliver the latest data to world leaders ... event brings together leaders at the forefront of the ... lung imaging. "The quality of the ...
(Date:3/7/2017)... BRIGHTON, England , March 7, 2017 Brandwatch ... been chosen by The Prince,s Trust to uncover insights ... insights across The Trust. The UK,s leading youth charity ... track social campaign results and get a better understanding of the ... ...
(Date:3/6/2017)... 2017 Mintigo , the leader ... Predictive Sales Coach TM , its new artificial ... into Salesforce. This unique AI application will allow ... with deep knowledge of their customers and prospects ... Predictive Sales Coach extends Mintigo,s existing customer success ...
Breaking Biology News(10 mins):